A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
For more information about the trial above please contact the study team:
Principal Investigator, Brian Hess, at firstname.lastname@example.org.
Study Coordinator, Sarah Britton, at email@example.com, or please call +1 843-792-8856.
Trial opened at the following institutions: Medical University of South Carolina